reports
Chevron Corp: 1 director
A director at Chevron Corp sold 7,647 shares at 162.667USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Sensata Technologies Holding plc: 1 director
A director at Sensata Technologies Holding plc bought 268,310 shares at 39.642USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Danske Bank AS: 1 director
A director at Danske Bank AS sold 168,499 shares at 197.490DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Eduspec Holdings Berhad: 1 director
A director at Eduspec Holdings Berhad bought 22,400,000 shares at 0.147MYR and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Inari Amertron Bhd: 1 director
A director at Inari Amertron Bhd sold 2,050,000 shares at 0.000MYR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Gritee Inc: 1 director
A director at Gritee Inc bought 9,000 shares at 2,891.956KRW and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Robust Mix Sustained a Strong Start to the Year
Robust Mix Sustained a Strong Start to the Year Robust Mix Sustained a Strong Start to the Year Net revenues of Euro 1,585 million, up 10.9% versus prior year, with total shipments of 3,560 units $1flat versus Q1 2023Adjusted EBIT(1) of Euro 442 million, up 14.8% versus prior year, with adjusted EBIT(1) margin of 27.9%Adjusted net profit(1) of Euro 352 million and adjusted diluted EPS(1) at Euro 1.95Adjusted EBITDA(1) of Euro 605 million, up 12.7% versus prior year, with adjusted EBITDA(1) margin of 38.2%Industrial free cash flow(1) generation of Euro 321 million “The start of the year wa...
Cellectar Biosciences to Announce First Quarter Financial Results and ...
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended March 31, 2024, on Tuesday, May 14, 2024. Management will also host a conference call with investors to discuss financial results and provi...
- ABGSC Credit Research
- Bendik Fougner Engebretsen
Premier, Inc. Reports Fiscal-Year 2024 Third-Quarter Results
CHARLOTTE, N.C.--(BUSINESS WIRE)-- Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2024 third quarter ended March 31, 2024. Third-quarter results: Total net revenue of $342.6 million; growth of 6% over the prior-year period GAAP net loss of $49.2 million, or $(0.36) per fully diluted share, which includes a $140.1 million goodwill, intangible and other long-lived assets impairment related to the company's Contigo Health business Adjusted earnings per share* of $0.55; flat compared to the p...
Connect Biopharma to Present a Late-Breaking Abstract at the American ...
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven researc...
Outcomes From Two New Head-to-Head Randomized Controlled Trials Involv...
Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American Urological Association Annual Meeting in San Antonio, TX, May 3 – 6, 2024, showcasing excellent patient experience* with the Prostatic Urethral Lift (PUL) with the UroLift™...
Vivid Seats Delivers Strong First Quarter Results
Vivid Seats Delivers Strong First Quarter Results Q1 2024 Marketplace GOV of >$1 Billion (+20% YoY) CHICAGO, May 07, 2024 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats” or “we”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today provided financial results for the first quarter ended March 31, 2024. “We are proud to deliver another strong quarter, showcasing the power of our core business and the momentum that has continued into 2024,” said...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Fina...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter 2024 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runw...
Radisson Intersects 9.70 g/t Gold Over 4.00 Metres and Adds Second Dri...
Radisson Intersects 9.70 g/t Gold Over 4.00 Metres and Adds Second Drill Rig at the O’Brien Gold Project in Quebec ROUYN-NORANDA, Quebec, May 07, 2024 (GLOBE NEWSWIRE) -- Radisson Mining Resources Inc. (TSX-V: RDS, OTCQB: RMRDF) (“Radisson” or the “Company”) is pleased to announce drill results and the acceleration of the ongoing drill program, with the mobilization of a second drill rig, to its 100%-owned O’Brien Gold Project located along the Larder-Lake-Cadillac Break (see and ), halfway between Rouyn-Noranda and Val-d’Or in Quebec, Canada. Highlights: Drill program ...
Radisson recoupe 9,70 g/t en Or sur 4,00 m et mobilise une seconde for...
Radisson recoupe 9,70 g/t en Or sur 4,00 m et mobilise une seconde foreuse au projet aurifère O’Brien au Québec ROUYN-NORANDA, Québec, 07 mai 2024 (GLOBE NEWSWIRE) -- Ressources minières Radisson Inc. (TSX-V : RDS, OTCQB : RMRDF) (« Radisson » ou la « Société ») est heureuse d'annoncer des résultats et l’accélération du programme de forage en cours avec la mobilisation d’une seconde foreuse au projet O'Brien détenu à 100% et localisé le long de la faille Larder-Lake-Cadillac (voir et ), à mi-chemin entre Rouyn-Noranda et Val-d’Or, au Québec, Canada. Faits saillants : Le program...
Design Therapeutics to Participate in the 2024 RBC Capital Markets Glo...
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be ar...
Ranger Energy Services, Inc. Announces Q1 2024 Results
HOUSTON--(BUSINESS WIRE)-- Ranger Energy Services, Inc. (NYSE: RNGR) (“Ranger” or the “Company”) announced today its results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights – Revenue of $136.9 million, a 13% decrease from $157.5 million in first quarter 2023 driven by declines in wireline completions and ancillary services – High specification rig revenue of $79.7 million, a 3% increase from $77.5 million in first quarter 2023 with additional growth anticipated in future quarters – Net loss of $0.8 million, or negative $0.03 per fully diluted share, a decrease...
Moody's Ratings assigns Baa2 rating to Kellanova's proposed EUR notes
Moody's Ratings (Moody's) today assigned a Baa2 rating to Kellanova's proposed €300 million of 10-year senior unsecured notes. Kellanova's Baa2 senior unsecured ratings and Prime-2 commercial paper rating remains unchanged. The outlook is stable. Kellanova will utilize the net proceeds for general...
Global Blue Releases the Monthly Tax Free Shopping Business Update for...
SIGNY, Switzerland--(BUSINESS WIRE)-- An accelerating worldwide recovery, compared to 2019 levels In Continental Europe, April 2024 recovery is ahead of Q1 ‘24 recovery, reaching 137%1 in April vs. 128%1 in Q1 ‘24, driven by a strong recovery in Spain (166%1), France (158%1) and Italy (145%1). Regarding origin markets, US shopper recovery accelerated, reaching 336%1 in April vs. 307%1 in Q1 ’24. The shift of the Ramadan period negatively impacted GCC recovery2, which stood at 198%1 in April vs. 277%1 in Q1 ‘24. In Asia Pacific, the recovery rate reached a record level at 194%1 in April v...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.